New insights in synovial angiogenesis

Joint Bone Spine

Volumn 77, Issue 1, 2010, Pages 13-19

  Szekanecz, Zoltán ^a   Besenyei, Timea ^a   Paragh, György ^a   Koch, Alisa E ^b,c  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Angiogenesis; Angiostasis; Rheumatoid arthritis; Vascular endothelial growth factor

Indexed keywords

2 METHOXYESTRADIOL; ANGIOPOIETIN; ANGIOSTATIN; ENDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR; INFLIXIMAB; INTERLEUKIN 13; INTERLEUKIN 4; MONOCLONAL ANTIBODY LM 609; PACLITAXEL; PIOGLITAZONE; ROFECOXIB; THALIDOMIDE; THROMBOSPONDIN 1; THROMBOSPONDIN 2; TOCILIZUMAB; VASCULOTROPIN; VATALANIB; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; HUMAN; NONHUMAN; RHEUMATOID ARTHRITIS; SHORT SURVEY; SYNOVIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; ARTHRITIS, RHEUMATOID; DISEASE MODELS, ANIMAL; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; SYNOVIAL MEMBRANE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 73449125837     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2009.05.011     Document Type: Short Survey

References (60)

1. Szekanecz Z., and Koch A.E. Vascular involvement in rheumatic diseases: 'vascular rheumatology'. Arthritis Res Ther 10 (2008) 224
2. Szekanecz Z., and Koch A.E. Mechanism of disease: angiogenesis in inflammatory diseases. Nat Clin Pract Rheumatol 3 (2007) 635-643
3. Lainer-Carr D., and Brahn E. Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis. Nat Clin Pract Rheumatol 3 (2007) 434-442
4. Folkman J., and Klagsbrun M. Angiogenic factors. Science 235 (1987) 442-447
5. Szekanecz Z., and Koch A.E. Chemokines and angiogenesis. Curr Opin Rheumatol 13 (2001) 202-208
6. Veale D.J., and Fearon U. Inhibition of angiogenic pathways in rheumatoid arthritis: potential for therapeutic targeting. Best Pract Res Clin Rheumatol 20 (2006) 941-947
7. Agarwal S.K., and Brenner M.B. Role of adhesion molecules in synovial inflammation. Curr Opin Rheumatol 18 (2006) 268-276
8. Szekanecz Z., and Koch A.E. Macrophages and their products in rheumatoid arthritis. Curr Opin Rheumatol 19 (2007) 289-295
9. Koch A.E., Harlow L.A., Haines G.K., et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 152 (1994) 4149-4156
10. Kiselyov A., Balakin K.V., and Tkachenko S.E. VEGF/VEGFR signaling as a target for inhibiting angiogenesis. Expert Opin Investig Drugs 16 (2007) 83-107
11. Taylor P.C., and Sivakumar B. Hypoxia and angiogenesis in rheumatoid arthritis. Curr Opin Rheumatol 17 (2005) 293-298
12. Giatromanolaki A., Sivridis E., Maltezos E., et al. Upregulated hypoxia inducible factor-1α and -2α pathway in rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 5 (2003) R193-R198
13. Arany Z., Foo S.Y., Ma Y., et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 451 (2008) 1008-1012
14. Honorati M.C., Neri S., Cattini L., et al. Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts. Osteoarthritis Cartilage 14 (2006) 345-352
15. Strieter R.M., Polverini P.J., Kunkel S.L., et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 270 (1995) 27348-27357
16. Pablos J.L., Santiago B., Galindo M., et al. Synoviocyte-derived CXCL12 is displayed on endothelium and induces angiogenesis in rheumatoid arthritis. J Immunol 170 (2003) 2147-2152
17. Salcedo R., Ponce M.L., Young H.A., et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96 (2000) 34-40
18. Nanki T., Hayashida K., El-Gabalawy H.S., et al. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T-cell accumulation in rheumatoid arthritis synovium. J Immunol 165 (2000) 6590-6598
19. Madri J.A., and Williams K.S. Capillary endothelial cell cultures: phenotypic modulation by matrix components. J Cell Biol 97 (1983) 153-165
20. Imhof B.A., and Aurrand-Lions M. Adhesion mechanisms regulating the migration of monocytes. Nat Rev Immunol 4 (2004) 432-444
21. Koch A.E., Halloran M.M., Haskell C.J., et al. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 376 (1995) 517-519
22. Brooks P.C., Clark R.A., and Cheresh D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264 (1994) 569-571
23. Naik T.U., Naik M.U., and Naik U.P. Junctional adhesion molecules in angiogenesis. Front Biosci 13 (2008) 258-262
24. Jacq L., Garnier S., Dieudé P., et al. The ITGAV rs3738919-C allele is associated with rheumatoid arthritis in the European Caucasian population: a family-based study. Arthritis Res Ther 9 (2007) R63
25. Shahrara S., Castro-Rueda H.P., Haines G.K., et al. Differential expression of the FAK family kinases in rheumatoid arthritis and osteoarthritis synovial tissues. Arthritis Res Ther 9 (2007) R112
26. Kneilling M., Hültner L., Pichler B.J., et al. Targeted mast cell silencing protects against joint destruction and angiogenesis in experimental arthritis in mice. Arthritis Rheum 56 (2007) 1806-1816
27. Brennan F., and Beech J. Update on cytokines in rheumatoid arthritis. Curr Opin Rheumatol 19 (2007) 296-301
28. Markham T., Mullan R., Golden-Mason L., et al. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. J Am Acad Dermatol 54 (2006) 1003-1012
29. Nakahara H., Song J., Sugimoto M., et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 48 (2003) 1521-1529
30. Amin M.A., Mansfield P.J., Pakozdi A., et al. Interleukin-18 induces angiogenic factors in rheumatoid arthritis synovial tissue fibroblasts via distinct signaling pathways. Arthritis Rheum 56 (2007) 1787-1797
31. Fearon U., Mullan R., Markham T., et al. Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures. Arthritis Rheum 54 (2006) 3152-3162
32. Amin M.A., Volpert O.V., Woods J.M., et al. Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase. Circ Res 93 (2003) 321-329
33. Morand E.F., Leech M., and Bernhagen J. MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov 5 (2006) 399-410
34. Koch A.E., and Distler O. Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther 9 Suppl. 2 (2007) S3
35. Mullan R.H., Bresnihan B., Golden-Mason L., et al. Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment and matrix degradation in rheumatoid arthritis through an NF-κB-dependent signal transduction pathway. Arthritis Rheum 54 (2006) 105-114
36. Hong K.H., Cho M.L., Min S.Y., et al. Effect of interleukin-4 on vascular endothelial growth factor production in rheumatoid synovial fibroblasts. Clin Exp Immunol 147 (2007) 573-579
37. Boulday G., Haskova Z., Reinders M.E., et al. Vascular endothelial growth factor-induced signaling pathways in endothelial cells that mediate overexpression of the chemokine IFN-gamma-inducible protein of 10 kDa in vitro and in vivo. J Immunol 176 (2006) 3098-3107
38. Vicari A.P., Ait-Yahia S., Chemin K., et al. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol 165 (2000) 1992-2000
39. Yin G., Liu W., An P., et al. Endostatin gene transfer inhibits joint angiogenesis and pannus formation in inflammatory arthritis. Mol Ther 5 (2002) 547-554
40. Sumariwalla P.F., Cao Y., Wu H.L., et al. The angiogenesis inhibitor protease-activated kringles 1-5 reduces the severity of murine collagen-induced arthritis. Arthritis Res Ther 5 (2003) R32-R39
41. Wang C.R., Chen S.Y., Shiau A.L., et al. Upregulation of kallistatin expression in rheumatoid joints. J Rheumatol 34 (2007) 2171-2176
42. Mundel T.M., and Kalluri R. Type IV collagen-derived angiogenesis inhibitors. Microvasc Res 74 (2007) 85-89
43. Park Y.W., Kang Y.M., Butterfield J., et al. Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in rheumatoid arthritis. Am J Pathol 165 (2004) 2087-2098
44. Haas C.S., Amin M.A., Allen B.B., et al. Inhibition of angiogenesis by interleukin-4 gene therapy in rat adjuvant-induced arthritis. Arthritis Rheum 54 (2006) 2402-2414
45. Haas C.S., Amin M.A., Ruth J.H., et al. In vivo inhibition of angiogenesis by interleukin-13 gene therapy in a rat model of rheumatoid arthritis. Arthritis Rheum 56 (2007) 2535-2548
46. Mabjeesh N.J., Escuin D., LaVallee T.M., et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3 (2003) 363-375
47. Issekutz A.C., and Sapru K. Modulation of adjuvant arthritis in the rat by 2-methoxyestradiol: an effect independent of an anti-angiogenic action. Int Immunopharmacol 8 (2008) 708-716
48. Manley P.W., Martiny-Baron G., Schlaeppi J.M., et al. Therapies directed at vascular endothelial growth factor. Expert Opin Investig Drugs 11 (2002) 1715-1736
49. Grosios K., Wood J., Esser R., et al. Angiogenesis inhibition by the novel VEGF tyrosine kinase inhibitor. PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis. Inflamm Res 53 (2004) 133-142
50. Guttmann-Raviv N., Shraga-Heled N., Varshavsky A., et al. Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis. J Biol Chem 282 (2007) 26294-26305
51. Yeo E.J., Chun Y.S., Cho Y.S., et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95 (2003) 516-525
52. Chen Y., Donnelly E., Kobayashi H., et al. Gene therapy targeting the Tie2 function ameliorates collagen-induced arthritis and protects against bone destruction. Arthritis Rheum 52 (2005) 1585-1594
53. Wente M.N., Keane M.P., Burdick M.D., et al. Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett 241 (2006) 221-227
54. Yin Y., Huang L., Zhao X., et al. AMD3100 mobilizes endothelial progenitor cells in mice, but inhibits its biological functions by blocking an autocrine/paracrine regulatory loop of stromal cell derived factor-1 in vitro. J Cardiovasc Pharmacol 50 (2007) 61-67
55. Skotnicki J.S., Zask A., Nelson F.C., et al. Design and synthetic considerations of matrix metalloproteinase inhibitors. Ann N Y Acad Sci 878 (1999) 61-72
56. Goedkoop A.Y., Kraan M.C., Picavet D.I., et al. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy. Arthritis Res Ther 6 (2004) R326-R334
57. D'Amato R.J., Loughnan M.S., Flynn E., et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91 (1994) 4082-4085
58. Ingber D., Fujita T., Kishimoto S., et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348 (1990) 555-557
59. McCarey D.W., Sattar N., and McInnes I.B. Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?. Arthritis Res Ther 7 (2005) 55-61
60. Bongartz T., Coras B., Vogt T., et al. Treatment of active psoriatic arthritis with the PPARγ ligand pioglitazone: an open-label pilot study. Rheumatology 44 (2005) 126-129